Europe Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-base

Europe Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)   

The influenza vaccines market in Europe is expected to grow from US$ 2,261.85 million in 2022 to US$ 3,424.02 million by 2028. It is estimated to grow at a CAGR of 7.2% from 2022 to 2028.

Increasing Investment by Top Market Players and Governments

Market players and governments are increasing their investments in vaccine development and immunization. In June 2021, The European Investment Bank signed a US$ 30.55 million global vaccine distribution agreement with biotech company Univercells to mass produce the COVID-19 vaccine at a new Belgian site. It helped build other vaccine factories around the region. In April 2022, the Bank provided a US$ 15.27 million loan to Italian biomedical research company IRBM to expand its vaccine production capacity and strengthen research on coronaviruses and other diseases. Thus, the increase in investment by top market players and governments is bolstering the influenza vaccines market.

Market Overview

Europe is the second largest market in the forecast period owing to factors such as rising geriatric population, increasing prevalence of flu and related illness, and high demand for the development of new vaccines in the region. In addition, growing funding for research & development activities is likely to add more opportunities in coming years, in the region. The pharmaceutical industry is continuously expanding in the UK. Under the UK’s pharmaceutical industry, over 610 companies are operating. According to Office National Statistics, 610 companies were operating in the UK in 2018. It has over 15 global companies headquartered in the UK. Also, nearly 41% of pharmaceutical production is exported to other countries and regions. Companies such as Astra Zeneca, Eli Lilly, and GSK have contributed significantly to the growth of pharmaceuticals and led research and development at a peak. The growth of these companies and expansions in the business segments is expected to influence market growth in the following years. The seasonal influenza vaccination programme was introduced in England during the late 1960s to protect those in clinical risk groups. During 2020 to 2021 an expanded offer was made which enabled people aged 50 to 64 years to receive the flu vaccine as part of an NHS funded programme. This offer will continue for this age group, as a temporary measure, for the 2021 to 2022 programme. Thus, the factors mentioned above are driving the market growth of influenza vaccines.
Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Europe Influenza Vaccines Market Segmentation

The Europe Influenza Vaccines Market is segmented into vaccine type, virus type, technology, route of administration, and country.
Based on vaccine type, the Europe influenza vaccines market is divided into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered the larger market share in 2022.
Based on virus type, the Europe influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger market share in 2022.
Based on technology, the Europe influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger market share in 2022.
Based on route of administration, the Europe influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger market share in 2022.
Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, and the rest of Europe. The UK dominated the market share in 2022.
AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the influenza vaccines market in Europe.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe Influenza Vaccines Market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe Influenza Vaccines Market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Influenza Vaccines Market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution